Endothelin-1 and Diabetic Complications: Focus on the Vasculature

Overview

Journal Pharmacol Res

Publisher Elsevier

Specialty Pharmacology

Date 2011 Feb 5

PMID 21292003

Citations 57

Authors

Adviye Ergul

Affiliations

Soon will be listed here.

Abstract

Diabetes is not only an endocrine but also a vascular disease. Cardiovascular complications are the leading cause of morbidity and mortality associated with diabetes. Diabetes affects both large and small vessels and hence diabetic complications are broadly classified as microvascular (retinopathy, nephropathy and neuropathy) and macrovascular (heart disease, stroke and peripheral arterial disease) complications. Endothelial dysfunction, defined as an imbalance of endothelium-derived vasoconstrictor and vasodilator substances, is a common denominator in the pathogenesis and progression of both macro and microvascular complications. While the pathophysiology of diabetic complications is complex, endothelin-1 (ET-1), a potent vasoconstrictor with proliferative, profibrotic, and proinflammatory properties, may contribute to many facets of diabetic vascular disease. This review will focus on the effects of ET-1 on function and structure of microvessels (retina, skin and mesenteric arteries) and macrovessels (coronary and cerebral arteries) and also discuss the relative role(s) of endothelin A (ET(A)) and ET(B) receptors in mediating ET-1 actions.

Citing Articles

From Orchard to Wellness: Unveiling the Health Effects of Sweet Cherry Nutrients.

Goncalves B, Aires A, Oliveira I, Baltazar M, Cosme F, Afonso S Nutrients. 2024; 16(21).

PMID: 39519493 PMC: 11547742. DOI: 10.3390/nu16213660.

Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?.

Odimegwu C, Uwaezuoke S, Chikani U, Mbanefo N, Adiele K, Nwolisa C Diabetes Metab Syndr Obes. 2024; 17:3557-3576.

PMID: 39323929 PMC: 11423826. DOI: 10.2147/DMSO.S479077.

Prognostic Value of Plasma Endothelin-1 in Predicting Worse Outcomes in Patients with Prediabetes and Diabetes and Stable Coronary Artery Diseases.

Yang C, Zhu C, Guo Y, Wu N, Dong Q, Xu R Diabetes Metab J. 2024; 48(5):993-1002.

PMID: 39165112 PMC: 11449811. DOI: 10.4093/dmj.2023.0410.

Advances and Perspectives in Relation to the Molecular Basis of Diabetic Retinopathy-A Review.

Blaszkiewicz M, Walulik A, Florek K, Gorecki I, Slawatyniec O, Gomulka K Biomedicines. 2023; 11(11).

PMID: 38001952 PMC: 10669459. DOI: 10.3390/biomedicines11112951.

Roles of mitochondrial dynamics and mitophagy in diabetic myocardial microvascular injury.

Wang T, Wang X, Fu T, Ma Y, Wang Q, Zhang S Cell Stress Chaperones. 2023; 28(6):675-688.

PMID: 37755621 PMC: 10746668. DOI: 10.1007/s12192-023-01384-3.

References

Turgut F, Bolton W . Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010; 55(5):928-40. DOI: 10.1053/j.ajkd.2009.11.021. View

Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S . Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32 Suppl 2:S314-21. PMC: 2811443. DOI: 10.2337/dc09-S330. View

Dumont A, Dumont R, McNeill J, Kassell N, Sutherland G, Verma S . Chronic endothelin antagonism restores cerebrovascular function in diabetes. Neurosurgery. 2003; 52(3):653-60; discussion 659-60. DOI: 10.1227/01.neu.0000048187.74897.7e. View

Alabadi J, Miranda F, Llorens S, Centeno J, Marrachelli V, Alborch E . Mechanisms underlying diabetes enhancement of endothelin-1-induced contraction in rabbit basilar artery. Eur J Pharmacol. 2004; 486(3):289-96. DOI: 10.1016/j.ejphar.2004.01.005. View

Wu Y, Feng B, Chen S, Zuo Y, Chakrabarti S . Glucose-induced endothelin-1 expression is regulated by ERK5 in the endothelial cells and retina of diabetic rats. Can J Physiol Pharmacol. 2010; 88(6):607-15. DOI: 10.1139/Y10-033. View

Feng J, Liu Y, Khabbaz K, Hagberg R, Robich M, Clements R . Decreased contractile response to endothelin-1 of peripheral microvasculature from diabetic patients. Surgery. 2010; 149(2):247-52. PMC: 3000877. DOI: 10.1016/j.surg.2010.07.003. View

Verma S, Arikawa E, Lee S, Dumont A, Yao L, McNeill J . Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol. 2002; 80(10):980-6. DOI: 10.1139/y02-122. View

Iwasa S, Fan J, Shimokama T, Nagata M, Watanabe T . Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis. 1999; 146(1):93-100. DOI: 10.1016/s0021-9150(99)00134-3. View

Barton M, Haudenschild C, dUscio L, Shaw S, Munter K, Luscher T . Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998; 95(24):14367-72. PMC: 24379. DOI: 10.1073/pnas.95.24.14367. View

10.

Amiri F, Virdis A, Neves M, Iglarz M, Seidah N, Touyz R . Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004; 110(15):2233-40. DOI: 10.1161/01.CIR.0000144462.08345.B9. View

11.

Chakrabarti S, Cukiernik M, Mukherjee S, Chen S . Therapeutic potential of endothelin receptor antagonists in diabetes. Expert Opin Investig Drugs. 2000; 9(12):2873-88. DOI: 10.1517/13543784.9.12.2873. View

12.

Haak T, Jungmann E, Felber A, Hillmann U, Usadel K . Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens. 1992; 5(3):161-6. DOI: 10.1093/ajh/5.3.161. View

13.

Chakrabarti S, Gan X, Merry A, Karmazyn M, Sima A . Augmented retinal endothelin-1, endothelin-3, endothelinA and endothelinB gene expression in chronic diabetes. Curr Eye Res. 1998; 17(3):301-7. DOI: 10.1076/ceyr.17.3.301.5216. View

14.

Zimmermann P, Knot H, Stevenson A, Nelson M . Increased myogenic tone and diminished responsiveness to ATP-sensitive K+ channel openers in cerebral arteries from diabetic rats. Circ Res. 1997; 81(6):996-1004. DOI: 10.1161/01.res.81.6.996. View

15.

Matsumoto T, Yoshiyama S, Kobayashi T, Kamata K . Mechanisms underlying enhanced contractile response to endothelin-1 in diabetic rat basilar artery. Peptides. 2004; 25(11):1985-94. DOI: 10.1016/j.peptides.2004.07.001. View

16.

Arrick D, Sharpe G, Sun H, Mayhan W . Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase. Microvasc Res. 2006; 73(1):1-6. DOI: 10.1016/j.mvr.2006.08.001. View

17.

Matsumoto T, Kobayashi T, Kamata K . Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res. 2008; 44(2):41-55. DOI: 10.1540/jsmr.44.41. View

18.

Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R . Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int. 2008; 74(1):91-100. DOI: 10.1038/ki.2008.112. View

19.

Rodriguez-Vita J, Ruiz-Ortega M, Ruperez M, Esteban V, Sanchez-Lopez E, Plaza J . Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res. 2005; 97(2):125-34. DOI: 10.1161/01.RES.0000174614.74469.83. View

20.

Khamaisi M, Dahan R, Hamed S, Abassi Z, Heyman S, Raz I . Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology. 2008; 150(3):1440-9. DOI: 10.1210/en.2008-0524. View